Oncology Institute, Inc. (TOI)
NASDAQ:TOI
Want to see TOI full AI Analyst Report?
Total Valuation
Oncology Institute has a market cap or net worth of $397.93M. The enterprise value is $393.90M.
Market Cap$397.93M
Enterprise Value$393.90M
Share Statistics
Oncology Institute has 99,982,930 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding99,982,930
Owned by Insiders24.20%
Owned by Institutions12.22%
Financial Efficiency
Oncology Institute’s return on equity (ROE) is 3.86 and return on invested capital (ROIC) is -35.70%.
Return on Equity (ROE)3.86
Return on Assets (ROA)-0.37
Return on Invested Capital (ROIC)-35.70%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee609.37K
Profits Per Employee-73.46K
Employee Count825
Asset Turnover3.05
Inventory Turnover25.26
Valuation Ratios
The current PE Ratio of Oncology Institute is ―. Oncology Institute’s PEG ratio is 2.27.
PE Ratio―
PS Ratio6.54
PB Ratio-209.23
Price to Fair Value-209.23
Price to FCF-118.37
Price to Operating Cash Flow-185.74
PEG Ratio2.27
Income Statement
In the last 12 months, Oncology Institute had revenue of 502.73M and earned -60.61M in profits. Earnings per share was -0.54.
Revenue502.73M
Gross Profit76.44M
Operating Income-36.08M
Pretax Income-60.74M
Net Income-60.61M
EBITDA-42.52M
Earnings Per Share (EPS)-0.54
Cash Flow
In the last 12 months, operating cash flow was -21.81M and capital expenditures -3.91M, giving a free cash flow of -25.73M billion.
Operating Cash Flow-21.81M
Free Cash Flow-25.73M
Free Cash Flow per Share-0.26
Dividends & Yields
Oncology Institute pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.61
52-Week Price Change33.11%
50-Day Moving Average2.96
200-Day Moving Average3.40
Relative Strength Index (RSI)64.50
Average Volume (3m)2.12M
Important Dates
Oncology Institute upcoming earnings date is Aug 11, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 11, 2026
Ex-Dividend Date―
Financial Position
Oncology Institute as a current ratio of 1.59, with Debt / Equity ratio of -161.17%
Current Ratio1.59
Quick Ratio1.35
Debt to Market Cap0.02
Net Debt to EBITDA-1.65
Interest Coverage Ratio-3.20
Taxes
In the past 12 months, Oncology Institute has paid -131.00K in taxes.
Income Tax-131.00K
Effective Tax Rate<0.01
Enterprise Valuation
Oncology Institute EV to EBITDA ratio is -79.01, with an EV/FCF ratio of -120.89.
EV to Sales6.68
EV to EBITDA-79.01
EV to Free Cash Flow-120.89
EV to Operating Cash Flow-136.62
Balance Sheet
Oncology Institute has $30.28M in cash and marketable securities with $26.25M in debt, giving a net cash position of $4.03M billion.
Cash & Marketable Securities$30.28M
Total Debt$26.25M
Net Cash$4.03M
Net Cash Per Share$0.04
Tangible Book Value Per Share-$0.04
Margins
Gross margin is 14.82%, with operating margin of -7.18%, and net profit margin of -12.06%.
Gross Margin14.82%
Operating Margin-7.18%
Pretax Margin-12.08%
Net Profit Margin-12.06%
EBITDA Margin-8.46%
EBIT Margin-9.84%
Analyst Forecast
The average price target for Oncology Institute is $7.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.00
Price Target Upside81.82% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast35.37%
EPS Growth Forecast46.10%